An independent validation cohort of patients with NSCLC revealed that the frequency of baseline CD57+CD8+ T cells was higher in DCB group and had high sensitivity and specificity for predicting the responsiveness to ICIs, with a determined cutoff value of 12.85%. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.